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1. Introduction  
Epilepsy is one of the most common chronic diseases accompanying mankind for centuries. 
Approximately 1% children in Europe have been born to the women suffering from 
epilepsy. For epileptic women is important to obtain appropriate information about 
possibility to have children and about risks connected with their pregnancy. A population-
based cohort study in Finland (Artama et al., 2006) suggested decreased birth rate among 
patients with epilepsy.  As both, disease and treatment, may induce inborn defect, it is 
essential to diminish their negative effects. Every chronic treatment during pregnancy 
increases estimation of the risk to offspring. Risk perception during pregnancy is individual, 
however almost 35% of women according to the study (Helbig et al., 2010) investigating 
factors important in the family planning decided to have fewer children. They were afraid 
about transfer epilepsy onto the offspring or disability to care for a child. Another factor 
having effect on their decision is teratogenicity of drugs used for treatment. Women with 
epilepsy may benefit from discussion with their healthcare provider about the impact their 
epilepsy may have on children. As almost 50% pregnancies in women with epilepsy in USA 
(Davis et al., 2008) are not intended, relevant information in right time may decrease the 
number of elective abortion. 
Every physician should be informed about risk to the fetus that is associated with seizures 
and drugs used for treatment during pregnancy. Drug used in girls and young women 
should be chosen with the respect to the future reproduction, because the use of anti-
epileptic drugs (AED) in women with epilepsy is in fact a balance between seizure control 
and adverse effects of drugs. 
2. History 
Modern treatment of epilepsy started during the19th century. The first drug introduced for 
treatment of epilepsy was potassium bromide that was widely used in USA and Europe 
during the second half of the 19th century. Another drug that was introduced at the 
beginning of 20th century was phenobarbital.  Hydantoins has been used since 1938. Many 
new drugs were discovered subsequently. Apart from the fact, that anticonvulsant drugs 
have been used for many years, their embryotoxicity was not be described before 60th, 
when first case reports were published (Meadow, 1968; Müller-Küppers, 1963; Centa & 
Rasore-Quartino, 1965; Massey, 1966). Fetal hydantoin syndrome was described in 1975 by 
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Hanson and Smith. Similar inborn defects were described for all older anticonvulsant drugs 
(primidone, valproate, phenobarbital, phenytoin, carbamazepine, trimethadion). The 
frequency and severity of defects associated with use trimethadion were so high to warrant 
consideration of early elective termination of pregnancy. The teratogenic mechanism of 
AEDs is only partially understood.  
2.1 Fetal anticonvulsant syndrome 
Fetal anticonvulsant syndrome is associated with exposure to dilantin, diphenylhydantoin, 
phenytoin, hydantoin, and valproic acid during 1st trimester of pregnancy, in lower degree 
also with other (carbamazepine). The abnormalities include (Jones, 1997; Žižka, 1997; Ornoy, 
2009):  
a. An increase of major congenital anomalies: congenital heart defects (septal defects, 
tetratology of Fallot, aortic coarctation etc.), cleft lip and palate, limb defects  with 
hypoplasia of nails and distal phalanges, finger-like thumbs, abnormal palmar creases, 
dislocation of hip, malformation of brain, especially neural tube defects. 
b. Specific syndrome including facial dysmorphy with wide anterior fontanel, ocular 
hypertelorism, broad, depressed nasal bridge, short nose with bowed upper lip, midface 
hypoplasia, epicantus, often also malformation of external genitalia and neural tube. 
c. Intrauterine growth retardation. 
d. Developmental disorders mainly affecting cognitive functions and behaviour. 
Small variations were noted according to the drug used. A significant association was seen 
between maternal use of valproic acid and spina bifida, and a weaker, non-significant one 
between carbamazepine and spina bifida. Facial clefts were associated with both 
diphenylhydantoin and phenobarbitone use and also with polytherapy (Källén et al., 1989). 
As AEDs have effect also on cognitive development, children exposed to valproate have 
increased risk of delayed early development in comparison to the control group (Bromley et 
al., 2010). It seems, that a distinctive pattern of abnormalities in infants is associated with the 
use of anticonvulsant drugs during pregnancy rather than with epilepsy itself (Holmes et 
al., 2001). 
3. Embryotoxicity and its evaluation 
3.1 Animal studies 
How embryotoxic potential of drug may be detected? The first opportunity is an animal 
study. Every drug has to be tested in animal studies with a respect to protect the unborn 
child from adverse effects. Animal studies can, but do not always, predict whether a drug 
will be teratogenic in humans.  Unfortunately, animal studies have shown as poor 
predictors in the case of thalidomide that did not produce malformations in rats and mice. 
On the other hand, some drugs have been found teratogenic in animals and not in humans. 
Therefore, minimally two different animal models are required for routine testing. Animals 
are often given far higher doses of drugs than humans would ever receive.  Interspecies 
differences regarding the teratogenicity of drugs, that can increase doubts about results, 
result from differing pharmacokinetic processes, different metabolites, concentration-time 
relationships in an embryo, placental transfer and elimination rate. The only way to 
ascertain the ultimate risk or safety of drugs during pregnancy is to verify them in human 
studies (Einarson & Koren, 1999). 
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3.2 Epidemiological studies 
As pregnant women cannot be enrolled in randomized, controlled studies from obvious 
ethical reasons, the teratogenicity have to be established in prospective or retrospective 
epidemiological studies. Data have been collected in a registry of birth defects (CDC- The 
International Clearinghouse for Birth Defects Monitoring Systems, EUROCAT - A European 
Network of Population-based Registries for the Epidemiological Surveillance of Congenital 
Anomalies), by specific registry collecting data about AEDs exposure  (EURAP- European 
and International Registry of Antiepileptic Drugs in Pregnancy, NAAPR - North American 
AED Pregnancy Registry) or  by services offering consultation about drug safety (OTIS - 
Organisation of Teratology Information Specialists, and ENTIS - European Network of 
Teratology Information Services).  Criterion for inclusion enrolment in prospective studies is 
AED use at time of conception or during first trimester, however before ultra-sonographic 
examination of normal development of child. Registry data can be used for monitoring that 
can identify specific risk.  
Retrospective studies using data from registry are utilized for case-control studies, where 
drug use among mothers whose babies express a specific malformation is compared with 
that of mothers whose babies do not. This method has a high sensitivity, but is more prone 
to bias. It is difficult to identify all concomitant factors those may affect development of 
birth defect. There is the evidence of partial memory and bias in the way women recall the 
drugs they took during pregnancy. Women suffering from chronic disease tend to recall 
their treatment better than women who took an over-the-counter drug. 
Prospective, controlled, epidemiological studies of the pregnancy outcomes of women who 
were treated by a particular drug during pregnancy are another possibility how is possible 
to evaluate risk. Even this type of research is not ideal, because the limited size of the studies 
means they do not have the statistical power to detect increased risk of rare malformations. 
Moreover indications for treatment and concurrent exposures are not standardized. 
The information received by drug manufactures is often a mix of prospective and 
retrospective case reports. The quality of the information about exposure is usually poor, 
reports of adverse fetal outcomes are more frequent as uneventful ones. 
The group of exposed pregnancies is usually compared to the control group performed by 
the pregnancies with normal outcome. The second possibility is the use of baseline risk of 
major malformation in population, that is 2.75% in USA  (according to CDC) and 2-3% in 
Europe (according to EUROCAT). Finally, the group of pregnant women exposed to drugs 
with minimal or no risk, represents the third type of control group.  
To monitor malformations, the statistical approach is used, that compares number of 
observed infants with specific type the inborn defect born during a specific time period with 
the number of infants expected to be born during that period. However, difference between 
the observed and the expected number can have many explanations: real change caused by 
introduction of a teratogenic agents, changes in detection and registration, fluctuation of 
specific malformation in time, wrong estimation of expected number of malformation etc. 
Therefore only limited number of conditions and set of standard malformations may be 
monitored. 
Teratological approach is focused on occurrence of specific malformations or their 
combinations (syndromes) those are present in exposed population or in all pregnant 
women. If malformation is very specific as phocomelia in thalidomide exposure, no baseline 
level of birth defects is needed (Källén & Hay, 1991). 
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Published case-reports have only limited significance, because causality between 
malformation and exposure can be only accidental. We need large exposed group for risk 
evaluation. The international cooperation is useful, because it allows collect many cases in 
relatively short time. For example, if the risk of major malformations in a given population 
is 3 percent, then at least 220 pregnancies with specific exposure and similar number of 
control pregnancies will be required to show that is increased risk by factor of 2.5, with a 
power of 80 percent (Koren, 2001). More than one thousand of cases are needed for risk 
assessment lower than 1%. 
It is generally accepted that assessing the risk of a substance to humans we need today:  
Case reports describing repeatedly a typical malformation pattern (syndrome).   
At least two large and well controlled epidemiological studies.  
Results of testing in laboratory mammals  following  the Good Laboratory Practice and 
WHO criteria, that serves only for confirming biological plausibility (Jelinek, 2005). 
FDA classification dividing drugs in 5 groups according to its impact to fetus is greatly 
simplifying. Merlob and Stahl (2002) concluded that this classification of drugs for 
teratogenic risk must be considered as  anachronistic and misleading way of approach and 
counselling, because the causation of inborn defects is multi-factorial and could not be 
limited to the qualification (if known) of a single factor, only. It is necessary perform the 
separate analysis of any individual case collecting as much relevant data as possible. 
3.3 Genetic background as a factor for inborn defect  
Drug metabolising enzymes and the genetic variants they carry are one of the factors that 
might be responsible for the efficacy and side effect of AED treatment in individual patients. 
They also modulate development and induce embryotoxicity. The speed and differences in 
metabolic inactivation may increase plasma level of AEDs up to embryotoxic threshold.  
Polymorphy in genes for enzymes involved in metabolic pathways for detoxification is 
suspected cause for development of birth defect in certain cases. For example, phenytoin 
toxicity is dependent on epoxide hydrolase activity, i.e. arena oxidase (Strickler et al., 1985) 
or on CYP2C19 specific cytochrome P-450 isoenzyme deficiency (Maier & Mayer, 1987). 
Valproate toxicity is increased in ornithine trans-carbamylase deficiency. Drug competition 
or the induction of microsomal enzymes may change AED plasma level and increase the 
risk. Higher risk for neural-tube defects such spina bifida and anencephaly after valproate 
or carbamazepine exposure has been assigned to the deficiency in folate dependent 
homocystein metabolism. Polymorphism of MTHFR (methylenetetrahydrofolate reductase) 
is associated with higher risk for anticonvulsant syndrome. Mothers who are homozygous 
for MTHRF genotype 677T were found to have three to four higher risk compared with 
those, that were homozygous for allele 677C. Other genes, for example MTR 2756, are 
involved in susceptibility to embryotoxic impairment (Steinlein, 2010). In present, we may 
conclude those woman having a child with vaproate fetal syndrome is in higher risk of 
malformed child for the next pregnancy (Tripp, 1981; Malm et al., 2002). In future, the 
genetic profile will be a goal for the optimal treatment of epileptic patients.  
3.4 Ischemia and re-perfusion injury 
The role of ischemia and re-perfusion producing tissue damage linked for example to neural 
tube defect has to become more evident in the past years. During an ischemic event, 
intracellular xantin dehydrogenase is converted to xantin oxidase. When the ischemia resolves, 
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xantin oxidase metabolised purines in uric acid. By-products of this reaction are super-oxide 
radicals. They produce tissue damage directly or indirectly.  As convulsions results in anoxia, 
higher rate of malformation was demonstrated in epileptic women without treatment and 
without seizure control in comparison with healthy population. Combination anoxia with 
teratogenic potential of drug even increases risk (Verrotti et al., 2006). 
4. Embryotoxicity of antiepileptic drugs (AEDs) 
4.1 First generation of antiepileptic drugs 
4.1.1 Phenytoin 
Phenytoin is the most widely used hydatoin derivate with antiepileptic effect. The 
teratogenic potential of hydantoin and its derivatives is known since 1968 (Meadow). The 
anomalies observed were described as “fetal hydantoin syndrome” (see above). In the case 
of phenytoin, it appears that fetal susceptibility correlates with the fetal level of the 
microsomal detoxifying enzyme epoxide hydrolase (Buehler et al., 1994). Developmental 
toxicity is probably caused by concentration-dependent bradycardia and hypoxia related 
damage of embryonic tissue (Azarbayjani & Danielson, 1998; Danielsson et al., 2000) 
resulting in alteration of gene expression minimally, if not everywhere, in craniofacial 
region (Gelineau-van Waes et al., 1999). In comparison with other AEDs, phenytoin 
produced higher incidence of fetal defects (20,9%) in animal study (Sullivan & McElhatton, 
1977), however risk occurring in epidemiological studies was lower. 
The risk of phenytoin exposure during pregnancy has been well documented. It has been 
estimated to be two to three folds higher that than of mothers without treatment as has been 
confirmed in several studies (Kluger & Meador, 2008; Schaefer et al., 2001). The prospective 
observation study made by 25 epilepsy centres in USA and UK from 1999 to 2004 determine 
risk of adverse outcomes for phenyltoin on 10.7% (including fetal death), and major 
malformation on 7.1% (Meador et al., 2006). Phenytoin mono-therapy increases the risk for 
cleft palate, but it has not been associated with microcephaly (Almgren et al., 2009). 
4.1.2 Barbiturates 
Barbiturates used for epilepsy treatment are phenobarbital, methylphenobarbital, and 
primidone, the pro-drug of phenobarbital to which is largely metabolized. In higher doses 
(50 mg/kg/day and more) primidone was teratogenic in mice increasing the incidence of 
cleft palate, other defects as exencephaly, fused ribs, and undescended testes were observed 
less frequently. The incidence of major malformation was dose dependent in primidone as 
well as phenobarbital (McElhatton & Sullivan, 1975; McElhaton et al., 1976; Fritz et al., 1976). 
After exposure to primidone, the malformation typical for AEDs have been described in 
many case reports and studies (Rating et al., 1982; Battino et al., 1998; Akšamija et al., 2009). 
Increased risk for major malformations associated with primidone exposure was 
demonstrated in large prospective study (Jones et al., 1992). North American Registry 
demonstrated a 6.5% risk after phenobarbital mono-therapy in comparison with 1.6% for 
control population (Kluger & Meador, 2008).  
4.1.3 Ethosuximide 
Ethosuximide is recommended drug for petit mal treatment, only. In animal studies the risk 
of major malformation was approximately as high as in primidone (Sullivan & McElhatton, 
1977). There are only a few report of the ethosuximide therapy during pregnancy. Study 
www.intechopen.com
  
Novel Treatment of Epilepsy 
 
188 
reporting on pregnancy outcome in ten women described two major malformation cleft lip 
in mothers treated ethosuximide in combination with primidone or phenobarbital (Kuhnz et 
al., 1984).  
4.2 Second generation of antiepileptic drugs 
4.2.1 Valproic acid (VPA) 
Valproic acid is widely used for treatment of a broad spectrum of epilepsy types, migraine 
as well as bipolar disorder. In utero exposure results in higher incidence of major and minor 
malformations. Proposed mechanism of action is related to the changes in methylation of 
histones (Tung & Winn, 2010). Epigenetic modification of them with hyperacetylation is 
accompanied with induction of apoptosis (Menegola et al., 2005; Di Renzo at al., 2010). 
Malformations occurred not only after valproic acid but also after valproate conjugates with 
anticonvulsant activity in animal model with different intensity (Spiegelstein et al., 2003; 
Okada et al., 2009). 
Fetal valproate syndrome was described in 1968 (Meadow, 1968). Drug teratogenicity was 
documented in many studies (Arpino at al., 2000; Bromfield et al., 2008). Dansky and Finnel 
(1991) summarized the knowledge on the reproductive outcome of patients treated with 
antiepileptic drugs during pregnancy that covered over 30 years in their meta-analysis. They 
demonstrated twofold to threefold increased risk of congenital malformation in epileptic 
women as compared with the general population. Similar finding, i.e. 2.5 times higher risk 
of having baby with malformation after valproic acid mono-therapy, was published in 
another large meta-analysis (Koren at al., 2006). Prospective observation study (Meador et 
al., 2006) that enrolled mother-child pairs from USA and UK demonstrated 17.4% 
malformations and 20.3% of serious adverse outcomes, that included fetal death in addition 
to malformations.  Chong and Bazil (2010) published meta-analysis including 59 studies and 
more than 65 000 pregnancies. They demonstrated high rate (10.73%) of malformations after 
VPA mono-therapy and after poly-therapy even 16.78%. Meador et al. (2009) published 
similar findings, i.e. 10.73% (95% CI: 8.16-13.29). The most frequent malformations were 
hernia, ear/neck/face malformations, cleft lip, and spina bifida. Nowadays, the studies have 
been focused on the correlation between dose and teratogenic effect. Higher doses than 1400 
mg/day have been proved to be more teratogenic (Vajda & Eadie, 2005). The evidence for 
higher risk is lacking for doses that are lower than 600mg per day, and risk gradually 
increases (Tomson & Battino, 2009; Diav-Citrin et al., 2008) and becomes more prominent at 
doses above 1000mg (Koren et al., 2006). EUROCAT study published in 2010 reveals 
significantly higher risk for those malformations after valproic acid mono-therapy. The 
adjusted odds ratios were as follows: spina bifida 12.7, atrial septal defect 2.5,   cleft palate 
5.2, hypospadia 4.8, polydactyly 2.2., craniosynostosis 6.8 (Jentink et al., 2010). 
4.2.2 Carbamazepine (CBZ) 
Carbamazepine is efficacious in treatment of a variety of CNS disorders, as well as epileptic 
seizures. CBZ is usually well tolerated and therefore is also used in pregnant women. 
Carbamazepine in dose that is corresponding to the therapeutic range in humans was not 
associated with negative pregnancy outcome in mice. It had no effect on fertility. Higher 
number of resorptions or higher risk of malformation was not detected (Christensen et al., 
2004). Similar findings were found in study after the exposure to higher doses (1.000, 1.500 and 
2.000 mg/kg). In those doses no specific pattern of malformation and no correlation between 
detected anomalies and dose were found (Finnel et al., 1986). The finding was supported also 
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by following studies (Wray et al., 1982; Fritz et al., 1976). On the other hand, Sullivan and 
McElhatton (1977) demonstrated higher frequency of malformation in exposed mice (4.7% 
compared with 1.3% in controls). Afshar end co-workers (2010) described specific eye 
malformations in mice after carbamazepine exposure at clinically comparable doses.  
Exposure to the carbamazepine was found to increase malformation rate in several studies 
(Diav-Citrin et al., 2001). Ornoy and Cohen (1996) described typical carbamazepine 
syndrome characterized by facial dysmorphic features and mild mental retardation, that did 
not seem to be related to presence of maternal convulsions but more to the hereditary 
factors. Rosa (1991) found higher (1%) risk for spina bifida in women used carbamazepine, 
that is ten times higher than in unexposed population.  Many case reports describing 
occurrence of spina bifida or eye malformation may support the opinion (Akšamija et al., 
2007; Källén, 1994; Sutcliffe et al., 1998). Meta-analysis using 16 prospective studies 
compared the risk of major malformation for CBZ mono-therapy and CBZ with other 
antiepileptic drugs, both in comparison to matched control pregnancies and to untreated 
epileptic pregnancies. It included 1255 CBZ exposed pregnancies. Study proved 2.89 fold-
increased risks of major congenital anomalies in children treated with CBZ as compared 
with children of healthy control. Rate of malformations was 2.34% in control population. 
The rate of major malformations was further increased in cases of women treated with 
combination of CBZ and other antiepileptic drugs, that was about 2-fold higher. Anomalies 
that risk was increased were neural tube defects, however cleft lip and cardiac defects were 
found, too. Decrease in gestational age at delivery was also revealed (Matalon et al., 2002). 
Case-control study  published by Jentink et al. (2010) using literature review and EUROCAT 
database demonstrated higher risk for spina bifida, only (odds ratio 2.6; 95% confidence 
interval 1.2 to 5.3). Difference was in classification of major malformations and exclusion of 
cases as compared with meta-analysis mentioned above. 
4.2.3 Oxcarbazepine (OCZ) 
Oxcarbazepine is similar to carbamazepine in chemical structure, but it is metabolized in 
different metabolic pathway. A monohydroxy-derivative (MHD) is responsible for its 
clinical efficacy. Premarketing studies showed an increase in congenital malformations in 
the offspring of rats   treated with oxcarbazepine at doses similar to those used in humans 
on a surface area basis. The abnormalities in the offspring included craniofacial, 
cardiovascular, and skeletal abnormalities. In rabbits, an increase in fetal mortality was 
noted at similar doses (Micromedex® 2.0, 2011).  Higher frequency of malformation was 
found also in mice (Bennet at al., 1996). 
In one report, mother using oxcarbazepine during all pregnancy gave birth to normal 
healthy girl and second pregnancy on the same therapy resulted also in healthy infant 
(Eisenschenk, 2006). Data from Argentina register revealed 35 pregnancies exposed to 
oxcarbazepine in mono-therapy resulted in the delivery of healthy infants. Of the 20 
pregnancies exposed to oxcarbamazepine in combination with other AEDs only one 
malformed child was reported: a cardiac malformation in a newborn exposed to 
phenobarbital and oxcarbamazepine (Meischenguiser et al., 2004). An analysis of 248 
published pregnancies involving maternal exposure of oxcarbamazepine in mono-therapy 
and 61 in poly-therapy did not find an increased incidence of malformations in exposed 
infants. Malformation rate was 2.4%, the same as malformation rate reported in the general 
population. In poly-therapy the risk was 6.6% (Montouris, 2005). The author notes that the 
available data are not sufficiently large to draw definitive conclusions.  
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4.2.4 Benzodiazepines  
Benzodiazepines are widely used as tranquilisers, hypnotics as well as AEDs.  For epilepsy 
treatment are used currently diazepam, clonazepam, clobazam, and sultiam. Diazepam 
cross easily placenta and it is present in blood in three time higher level than in mother.  
Case control studies indicate higher risk of major malformation, especially oral cleft, 
however meta-analysis demonstrated no association between benzodiazepine exposure and 
major malformations. Short exposure is possible, however long term treatment is associated 
with withdrawal symptoms (Robert-Gnansia & Schaefer, 2007). Shepard and Lamire (2004) 
refer that clonazepam in animal studies demonstrated no fetal effect.  There are only few 
epidemiological studies. Ornoy et al. (1998) found no increase of malformation in 69 women. 
No relevant information was published about clobazam and sultiam.  
4.3 Third generation of antiepileptic drugs  
4.3.1 Lamotrigine (LTG) 
The manufacturer (GlaxoSmithKline, Research Triangle Park, NC, USA) reported teratology 
testing in mice, rats, and rabbits at oral doses. There was no increase in congenital 
malformations in any of these species. Top doses were 1.3 (mice), 0.5 (rats), and 1.1 (rabbits) 
times the maintenance dose recommended for humans on a mg/m2 basis. Maternal and 
fetal toxicity (delayed ossification and decreased weight) were seen at the high doses in the 
rodent studies (Micromedex® 2.0, 2011). Lamotrigine in reproductive toxicity study given 
intravenously in the mouse did not produce malformation except for highest doses that 
were toxic for mother (50 - 300 mg/kg/day). Resorption and reduction of fetal weight were 
seen both being dose dependent. Skeletal malformation found in these studies were 
assigned to the maternal toxicity, however neural tube defects (anencephaly), malformation 
related to the cranial crest cells, and caudal dysgenesis were probably induced by 
lamotrigine (Padmanabhan et al., 2003).  Prenatal exposure to LTG induced altered brain 
structure in a dose-dependent manner at maternal plasma concentrations within the 
clinically occurring range (Manent et al., 2008).  
The manufacturer set up a registry to collect information on pregnant women exposed to 
lamotrigine.  A report from this registry extending till 31 March 2009 included 1439 
pregnancy outcomes after first trimester exposure to lamotrigine mono-therapy. There were 
35 pregnancies with congenital malformations, for a rate of 2.4% (95% CI 1.7- 3.4%). Among 
the defects reported were cleft lip and palate, clubfoot, hydronephrosis with megaureter, 
anencephaly, anal atresia, cardiac defects, limb defects, and an esophageal malformation. 
No relationship of malformation rate to lamotrigine dose was evident, and an evaluation of 
exposure level and malformation did not suggest a dose-response relationship. The 
Advisory Committee noted that the registry did not replicate a signal for orofacial clefts 
such as that reported from the AED Pregnancy Registry (discussed below) and that with 
more than 1000 pregnancies enrolled, the confidence was sufficiently narrow to exclude an 
appreciable increase in malformation risk (Cunnington & Messenheimer, 2007). Australian 
Pregnancy Register of Antiepileptic Drugs included 243 pregnancies exposed to lamotrigine. 
The analysis did not show statistically significant difference between the risk of fetal 
malformation and exposure to lamotrigine mono-therapy (Vajda et al., 2010). UK Epilepsy 
and Pregnancy Register enrolled 647 pregnancies exposed to lamotrigine. Malformation rate 
was 3.2%. When adjusted for age, parity, family history of malformations, periconceptional 
folic acid exposure and sex of infant odds ratio was 1.71 (95%CI 0.88 - 3.32). This study  
revealed positive dose response with malformation rate of 5,4 (95% CI 3.3-8.7%) for total 
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daily doses more than 200mg. Results of five registries and one large prospective study were 
published up to 2007. The prevalence of major malformations in North American AED 
Pregnancy Registry (NAAPR) was 2.7%, however higher prevalence of cleft lip and palate 
than that observed in control group (Holmes et al., 2006). In contrast the EUROCAT did not 
find an increased risk of orofacial clefts for mono-therapy, but for poly-therapy it was 
increased (OR: 1.43; 95%CI: 1.03-1.93). However, observed rate was low and absolute risk is 
minimal (Shor et al., 2007; Meador & Penovich, 2008). Later, Miskov et al. (2009) did not find 
an increase of birth defect in their small prospective study (23 pregnancies).  
4.3.2 Levetiracetam  
In preclinical studies presented by the sponsor, levetiracetam did not produce fertility 
impairment in male and female rats given up to 1800 mg/kg/d, which is six times the 
recommended human dose on a surface area basis. Pregnant rats given levetiracetam at 
doses similar to the human dose were born fetuses with an increased incidence of 
intrauterine growth retardation and minor skeletal abnormalities. No maternal toxicity was 
noted at this dose (Micromedex® 2.0, 2011). Saillenfait et al. (2007) described higher 
incidence of resorptions in rats at dose 500mg/kg/day and dose related decrease in fetal 
weight. They demonstrated malformations as super-numerable ribs, absent tail, anal atresia, 
cardiovascular defects, and impairment of ossification at dose 250mg/kg /day and higher, 
that was six fold higher than therapeutic dose for human and that was toxic for mother. 
Study in a mouse model did not reveal higher incidence of major malformations after 
levetiracetam treatment up to dose 2000mg/kg/day. There was higher frequency of 
resorptions at high doses (Isoherranen et al., 2003). 
Case reports on 3 pregnancies exposed to levetiracetam (Long, 2003) showed no adverse 
outcome. French et al. (2001) reported 23 women became pregnant during clinical trials. 
Eight pregnancies results in nine healthy offspring. Two babies had malformations, but both 
mothers were exposed also to other AEDs. Seven pregnancies resulted in spontaneous 
abortion and three women had voluntary termination. Prospective study (Johannessen et al., 
2005) described 7 children (2 pregnancies with mono-therapy, 5 pregnancies with poly-
therapy) without any malformation.   EURAP in Netherlands (ten Berg et al., 2005) reported 
11 pregnancies exposed to levetiracetam: one woman had the spontaneous abortion, and 
one pregnancy was elective terminated from social reasons. Nine live born children were 
without any malformations. The UK Epilepsy and Pregnancy Register (Hunt et al., 2006) 
identified 39 pregnancies exposed to levetiracetam mono-therapy and 78 in combination 
with at least one other AED. There were no congenital malformations in group with mono-
therapy. Longo et al. (2009) summarized accessible data revealing 147 patients. Of these 
patients 2% experienced a major malformation, 4.8% a minor anomaly. All of them were 
receiving poly-therapy.  
4.3.3 Topiramate 
As reported by the manufacturer (Janssen-Cilag), topiramate is teratogenic in mice, rats and 
rabbits. Similar findings revealed a study describing an adverse effect of topiramate 
(100mg/kg/day) on developing embryos in rats increasing  number of resorptions (Khouri, 
2005).  
Gentile (2009) reported on one pregnancy with normal outcome. Ornoy et al. (2008) reported 
on the outcome of 52 pregnancies where the mothers used topiramate at least during the 
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first trimester of pregnancy. The rate of spontaneous abortions (11.3%) was significantly 
higher in comparison to controls (2,8%). Although rate of major malformation was higher 
(9.8%), two cases were genetic in origin. One case from non-genetic was a baby whose 
mother used also valproic acid and clonazepam. Another case report (Vila Cerén et al., 2005) 
described the case of a neonate whose mother treated with topiramate during pregnancy at 
doses of 300 mg per day was born malformed child with oligodactyly and syndactyly. 
Prospective study (Hunt et al., 2008) following 203 pregnancies exposed to topiramate 
resulted in 178 live birth babies, 16 had major malformations. Three occurred in 70 
pregnancies in which the drug was in mono-therapy. Two other newborns were exposed to 
the drug as poly-therapy. Overall, the rate for oral clefts was 11 times the background rate. 
Hernandez-Diaz and co-workers (2010) reported 3.8% major malformations among 289 
women taking the drug in the first trimester that were enrolled by the North American AED 
Pregnancy Register. Risk ratio for major malformation was 2.8. They found also higher risk 
for cleft lip and lower birth weight. FDA now alerts on higher risk of cleft lip and palate.  
4.3.4 Other new antiepileptic drugs 
Risk assessment for following new antiepileptic drugs is not possible due to lack of 
experience. Information on few case reports was hardly even published.  Only preclinical 
studies on animals performed by producer have been accessible for some of them.  
Gabapentin:  Small ENTIS study identified five normal infants after exposure to gabapentin 
(De Santis et al., 2004). 
Vigabatrin (VGB): The animal experiments demonstrated significant teratogenic effect 
when drug was administered to mice during organogenesis (Padmanabhan et al., 2010). 
Lower doses were associated with disturbance of motor-cognitive behaviour and lower 
weight of pups, however higher caused abortions (Lombardo et al., 2005).  Since vigabatrin 
exposure has been associated with retina damage, two small studies examined children 
exposed in utero to drug demonstrated no clear ophthalmic abnormalities, However, 
sample was to small to be able to confirm safety for fetus (Sorri et al., 2005; Lawthom et al., 
2009). According to the FDA recommendation, the treatment may be only short-term 
(Chong & Bazil, 2010). 
Zonisamid teratogenicity was evaluated in six pregnant women. Five patients, two on 
mono-therapy and three on poly-therapy delivered healthy children. Malformed child with 
anencephaly was reported after zonisamid in combination with phenytoin. Together with 
above mentioned, there were 26 pregnancies reported, only. Two of them had 
malformations (7.7%) The other child was born with an atrial septal defect to the woman 
treated poly-therapy that included phenytoin and valproate (Ohtahara & Yamatogi, 2007).  
Pregabalin is a GABA analogue that inhibits with high affinity and selectivity the voltage 
dependent calcium channels. Animal study revealed increasing incidence of a specific 
tumour type (Selak, 2001) 
No information about  rufinamide, lacosamide, stripentol and tiagabin embryotoxicity has 
been published, yet. 
5. Trends in epilepsy treatment and our experience 
Study characterizing trends in prescribing antiepileptic drugs in Czech Republic in 
comparison with European countries and Australia compared used drug spectra from 1987 
to 2000. Utilization of barbiturates and succimide derivatives was decreasing. Hydantoins, 
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that utilization in Australia was steady, were in Europe decreasing, too. The valproic acid 
consumption was increasing as well as utilisation of third generation AEDs (Kořístková & 
Grundmann, 2005). The trends in usage corresponds to recommendation for general 
population, however valproic acid is the most teratogenic AEDs. Studies focused on girls or 
women in childbearing age demonstrated also changes in prescribed drugs and increase of 
lamotrigine prescribing in female (Ackers et al., 2009; Vajda et al., 2007). Proportion of 
women that were exposed to topiramate and levetiracetam was increasing, too (Vajda et al., 
2010). We recorded the same trends in treatment of epilepsy during pregnancy in our ten 
years experience of Czech Teratology Information Service (CZTIS) with inquiries about 
epilepsy treatment during pregnancy (Maňáková et al., 2006).. Lamotrigine was used in 
almost 30% of pregnant women, carbamazepine in 23.4%, and valproic acid in 21.3%, that 
correspond with above mentioned studies. New drugs as levetiracetam and topiramate 
were used for treatment of pregnant women in last years, too. 
6. Conclusions   
The management of the pregnant women suffering from epilepsy requires close cooperation 
between the neurologist and obstetrician. Women with epilepsy have a low complication 
rate except of that related to AEDs exposure (Borthen et al., 2009). All of them in 
childbearing age should be informed about the rates of teratogenicity of AEDs, possibility of 
increased seizure frequency during pregnancy, and the risks of the pregnancy and labour.  If 
almost half of pregnancies are not planned, the optimalization of treatment and consultation 
should be discussed with girls on beginning of their childbearing age. Since unplanned 
pregnancy is very often diagnosed after the most sensitive period of embryo development, 
when malformations are already developed, it makes no sense to change treatment. 
Exposure to antiepileptic drugs is not an indication for therapeutic abortion, even if they are 
teratogenic. Counselling is very important, because it helps to gain a realistic perspective of 
risk.  
The frequency of seizures is essentially the same as before pregnancy, however tonic-clonic 
convulsions should be avoided, because they are risky for mother and fetus. Seizures can 
cause trauma leading to ruptured fetal membranes or abruptio placentae (Pennell, 2003). 
Fortunately, with close monitoring and proper management, more than 90 percent of 
pregnancies in women with epilepsy will be uncomplicated. 
6.1 Optimization of treatment 
Optimization of treatment should be made before pregnancy. Diagnosis of epilepsy should 
be confirmed and indication for treatment with AEDs re-assessed. The possibility of AED 
gradual withdrawal should be considered in appropriate clinical setting prior to conception. 
The AED treatment should be optimized also prior to conception. Selection should be made 
the most appropriate for patient. Changing during pregnancy is rarely justified, risk 
probably overweight potential gain (Tomson & Hiilesmaa, 2007). To ascertain whether 
epilepsy remains in remission enough time before conception is required. 
Drugs of choice during pregnancy are considered lamotrigine and carbamazepine. Drugs 
should be given in mono-therapy with the lowest effective dose. Poly-therapy should be 
avoided because of proved increase of risk. Effective dose and optimal concentration of the 
drug before pregnancy should be documented. Monitoring of drug plasma concentration 
have to be more frequent, minimally once during trimester.  Good compliance with 
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treatment is essential. Lamotrigine, levetiracetam, and topiramate plasma levels are 
changing (decreasing) during pregnancy, so adjustment of therapeutic dose during 
pregnancy is needed. Valproic acid should be avoided, if it is possible. However, adequate 
seizure control is the primary goal.  If it is only drug giving satisfactory control of seizures, 
valproic acid should be used of the lowest possible day dose (optimum under 600mg/day) 
divided into three doses to minimize negative influence to fetus. Pregnancy should be 
considered of high risk and must have appropriate follow up (Ornoy, 2009). 
The second level (expert) ultra-sonography may justified normal development or detect 
most neural tube defects and about two third of other major malformations. 
6.2 Folic acid supplementation and its profit 
Low serum folic acid level in epileptic mothers is associated with an increased risk of 
congenital malformations in their offspring (Ogava et al., 1991). Population studies 
demonstrate benefit from fortification of cereal products by folic acid (De Walls et al., 2007) 
or supplementation before planed pregnancy. Daily consumption of supplements 
containing 400 micrograms of folic acid in the periconception period may reduce the risk of 
neural tube defects in general population by as much as 70% (Morin et al., 2002). If risk of 
malformation is higher in women with low plasma level of folic acid, periconceptional 
supplementation with minimally 0.4 mg folic acid per day in AEDs exposed population is 
considered prophylactic. The measurement that determines intra-erythrocythal level of folic 
acid may help with definition of optimal dose.  Results suggest, that 5 mg/day folic acid as 
preconception supplementation in women with epilepsy is effective to balance the impact of 
AEDs on folate metabolism (Bauer et al., 2010). Folate profylaxis is recommended to all 
women taking antiepileptic drugs.  Treatment with dose up to 5mg/day should start before 
planned pregnancy and continued minimally to the end of first trimester. 
6.3 Vitamin K supplementation 
Management strategies include also the prenatal use vitamin K. Vitamin K 10 mg per day 
orally should be administered in the last 4 weeks of pregnancy for women taking hepatic 
enzyme-inducing AEDs (phenytoin, phenobarbital, primidone, carbamazepine, topiramate, 
and oxcarbazepine). The newborn should receive vitamin K 1 mg intravenously or 
intramuscularly regardless of maternal AED exposure. 
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